Is Egrifta (Tesamorelin) Legal in Florida?

What Exactly Is Tesamorelin and Why Does Its Legal Status Matter?

Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone (GHRH). It binds pituitary GHRH receptors, stimulating pulsatile growth hormone secretion without the continuous-elevation profile associated with exogenous GH administration. The FDA approved the branded product Egrifta (tesamorelin 1 mg) in November 2010 and later approved Egrifta SV (tesamorelin 2 mg) in 2019, both specifically for reducing excess abdominal fat in adults with HIV-associated lipodystrophy (HALS).

Legal status matters here because tesamorelin sits at the intersection of three separate regulatory layers: federal FDA approval, federal compounding pharmacy law (Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act), and Florida state pharmacy and medical-practice statutes. Getting any one of these wrong exposes patients and prescribers to real legal risk.

The Core Legal Distinction: Branded vs. Compounded

Branded Egrifta and Egrifta SV are prescription drugs manufactured by Theratechnologies under a full FDA New Drug Application (NDA). Prescribing or dispensing the branded product in Florida requires only a valid prescriber-patient relationship and a licensed Florida pharmacy. No special permit is needed beyond standard Rx dispensing rules.

Compounded tesamorelin is different. It may be prepared by a licensed 503A or 503B pharmacy, but the legal permissibility depends on several conditions discussed in detail below. The distinction between these two pathways is not a technicality; it determines which federal and state rules apply.

Federal Legal Framework for Egrifta (Tesamorelin)

FDA Approval and Indication

The FDA-approved indication is narrow: reduction of excess abdominal fat in HIV-positive adults with lipodystrophy. The original NDA review documents are publicly available at FDA and confirm the 2 mg/day subcutaneous dosing regimen studied in the Theratechnologies Phase 3 program.

Two key Phase 3 trials, F-30 and F-31 (combined N = 816), showed that tesamorelin 2 mg/day subcutaneous injection reduced visceral adipose tissue (VAT) by a mean of 15.2% vs. 1.4% for placebo at 26 weeks, as measured by CT abdomen (P<0.0001) [1]. Trunk fat reductions correlated with IGF-1 normalization in the same cohort.

Schedule Status Under the Controlled Substances Act

Tesamorelin is not listed in DEA Schedules I through V. It is not an anabolic steroid under 21 U.S.C. 802(41). It is not a human growth hormone under the more restrictive provisions of 21 U.S.C. 333(e), which restrict GH prescribing to FDA-approved indications. The FDA's own FAQ on human growth hormone addresses HGH restrictions but does not place GHRH analogues like tesamorelin in the same statutory category. This distinction is clinically and legally significant.

503A Compounding (Patient-Specific Pharmacies)

Under Section 503A of the FD&C Act, a licensed pharmacist may compound a drug for an individual patient provided the drug is not on the FDA's "Difficult to Compound" list, is not on an active FDA Bulk Drug Substances (BDS) Category 2 or Category 3 list prohibiting its use, and is compounded pursuant to a valid, patient-specific prescription.

As of January 2025, tesamorelin does not appear on the FDA's 503A Bulks Nominated Substances list under a Category 2 or 3 prohibition. This means 503A pharmacies may, in principle, compound tesamorelin for an individual patient under a valid prescription. However, because an FDA-approved product (Egrifta) exists, the compounded version must not be made for the purpose of simply producing a copy of the approved drug, that would violate 503A's anti-copying provision [2].

503B Outsourcing Facilities

503B outsourcing facilities operate under stricter FDA oversight and may produce bulk compounded drugs for hospital or office administration without patient-specific prescriptions. The FDA's current 503B bulks list does not place tesamorelin on a prohibited substances list as of this writing. A licensed 503B facility in compliance with cGMP standards may therefore compound tesamorelin in batches for qualified dispensing.

The key constraint: the facility must hold an FDA 503B registration and must not be compounding a copy of Egrifta solely to avoid the branded product. Facilities routinely demonstrate clinical differentiation (altered delivery, dose, or vehicle) to satisfy this requirement.

Florida State Legal Framework

Florida Board of Pharmacy Rules

Florida pharmacy law is codified primarily in Chapter 465, Florida Statutes, and in the rules of the Florida Board of Pharmacy (Chapter 64B16, Florida Administrative Code). Florida Statute 465.003 defines "compounding" and restricts it to licensed pharmacists or practitioners acting within their scope of practice.

Florida has not enacted any statute or administrative rule specifically targeting tesamorelin, GHRH analogues, or peptides as a class beyond what federal law already requires. A Florida-licensed pharmacy that wishes to compound tesamorelin must comply with USP <797> sterile compounding standards, maintain appropriate licensure, and operate within the federal 503A or 503B framework.

Dispensing a prescription drug without a valid prescription in Florida constitutes a third-degree felony under Florida Statute 465.015(2)(b), punishable by up to 5 years imprisonment [3]. This applies to any dispensing entity regardless of whether the drug is FDA-approved or compounded.

Florida Telehealth Law and Tesamorelin Prescribing

Florida Statute 456.47 explicitly permits telehealth prescribing by licensed practitioners who have established an appropriate provider-patient relationship. A Florida-licensed physician, physician assistant, or advanced practice registered nurse (APRN) may evaluate a patient via a synchronous audiovisual telehealth platform and issue a prescription for tesamorelin (branded Egrifta) or for a compounded formulation from a licensed pharmacy.

The prescriber must document a valid clinical indication in the medical record. For the FDA-approved indication, that means documented HIV-associated lipodystrophy. Off-label prescribing for other conditions, such as age-related GH decline or body-composition optimization, is legally permissible for any Florida-licensed prescriber but may not be billable to insurance and carries additional professional-judgment obligations.

The Off-Label Prescribing Question

Physicians in Florida, as in all U.S. States, retain broad authority to prescribe approved drugs off-label based on clinical judgment. The FDA's guidance on off-label use confirms that "once a drug has been approved for marketing, a physician may prescribe it for uses or in patient populations that are not included in the approved labeling." This applies to Egrifta.

The complication arises when a prescriber wants to use compounded tesamorelin off-label. Compounding under 503A requires that the drug not be a copy of a commercially available product. If a prescriber needs a dose or concentration not available in the commercial Egrifta SV vial, a 503A pharmacist may compound that specific formulation, but the prescriber must document why the commercial product does not meet the patient's clinical needs.

A simple framework for Florida practitioners evaluating tesamorelin prescribing options:

1. HIV-associated lipodystrophy, insured patient. Prescribe branded Egrifta SV. Submit prior authorization. FDA-approved, legally straightforward.
2. HIV-associated lipodystrophy, uninsured or prior-auth denied. Licensed 503A compounding pharmacy can fill a patient-specific prescription for tesamorelin, provided the pharmacy documents clinical differentiation from the branded product.
3. Off-label indication (e.g., age-related GH decline). Branded Egrifta is prescribable off-label; insurance will not cover it. Compounded tesamorelin via 503A is permissible if the commercial product does not meet patient-specific needs; the prescriber must document this.
4. Batch supply for a clinic. A 503B outsourcing facility registered with the FDA may supply compounded tesamorelin in bulk for office administration.

How to Get Egrifta (Tesamorelin) in Florida: A Step-by-Step Guide

Step 1: Find a Licensed Florida Prescriber

Any Florida-licensed MD, DO, PA, or APRN with prescriptive authority can prescribe tesamorelin. Endocrinologists, infectious disease specialists, and hormone-specialist clinics are the most common prescribers. Telehealth platforms operating under Florida Statute 456.47 can serve patients statewide from a single licensed provider.

Step 2: Complete a Clinical Evaluation

Your prescriber should obtain a thorough history, review current medications, and order relevant labs before prescribing. For HALS, baseline VAT imaging (CT abdomen or DEXA-equivalent) and IGF-1 levels are standard. The Endocrine Society's 2019 clinical practice guideline on lipodystrophy syndromes recommends documenting HIV status, antiretroviral regimen, and metabolic parameters before initiating tesamorelin therapy [4].

Off-label evaluations should include fasting metabolic panel, IGF-1, and a discussion of risk versus benefit documented in the medical record.

Step 3: Obtain the Prescription

For branded Egrifta SV, any licensed Florida pharmacy with the drug in stock can fill the prescription. Several specialty pharmacies and mail-order pharmacies carry it. Expect prior-authorization requirements from most insurers.

For compounded tesamorelin, the prescriber should route the prescription to a licensed 503A pharmacy that holds Florida dispensing licensure. Verify that the pharmacy is registered with the Florida Board of Pharmacy and, if operating across state lines, holds the appropriate non-resident pharmacy permit.

Step 4: Confirm Pharmacy Credentials

The Florida Board of Pharmacy maintains a public license-verification database. Patients and practitioners can confirm a pharmacy's licensure status at Florida DBPR's license search portal. For 503B facilities, cross-reference with the FDA's registered outsourcing facilities list.

A pharmacy that cannot produce a valid Florida license and a DEA registration (for any controlled substances it dispenses) should not be dispensing tesamorelin or any other prescription product to Florida patients.

Step 5: Administration and Follow-Up

Egrifta SV is administered as a 2 mg subcutaneous injection once daily, typically into abdominal fat away from the navel. FDA prescribing information for Egrifta SV specifies injection site rotation to avoid lipohypertrophy [5]. IGF-1 should be checked at 3 months and the dose adjusted if levels exceed the upper limit of the age-adjusted normal range.

Risks, Contraindications, and What Florida Practitioners Must Document

Key Contraindications

Egrifta is contraindicated in patients with active malignancy, during pregnancy (Category X in the original labeling), and in those with pituitary tumor or pituitary surgery history. The FDA-approved label warns of fluid retention, arthralgia, and carpal tunnel syndrome as the most common adverse events seen in the key trials, occurring in 3.6% to 6.5% of tesamorelin-treated patients vs. <2% for placebo [5].

Documentation Requirements for Florida Prescribers

Florida's Medical Practice Act (Chapter 458, F.S.) requires practitioners to maintain adequate medical records that justify the course of treatment. For tesamorelin, this means:

• Documented diagnosis supporting the prescription
• Baseline and follow-up labs (IGF-1 minimum)
• Informed consent discussion, especially for off-label use
• Evidence that the chosen formulation (branded or compounded) is appropriate for the patient

The Florida Board of Medicine has not issued tesamorelin-specific guidance, but its general standard of care framework, which requires prescribers to act within their scope and maintain records justifying treatment, applies fully [6].

The Gray Area: Research-Grade Tesamorelin

Some websites sell tesamorelin labeled "for research use only" or "not for human use." Purchasing such material for personal injection in Florida is a legal gray area at best. The product is not manufactured under cGMP conditions, has no verified purity or sterility, and is not dispensed pursuant to a prescription. Using it constitutes obtaining a prescription drug without a valid prescription, which is a first-degree misdemeanor under Florida law. Florida law enforcement has pursued similar cases involving other peptides and research chemicals.

Insurance Coverage in Florida

Branded Egrifta SV carries a list price exceeding $5,000 per month. Coverage for the FDA-approved HALS indication is available through most major commercial plans in Florida, Medicare Part D (with prior authorization), and Florida Medicaid under the HIV/AIDS waiver program, though formulary tier and step-therapy requirements vary by plan.

A 2022 cost-effectiveness analysis published in Clinical Infectious Diseases found that tesamorelin's cost per QALY gained in HALS patients was approximately $180,000, above conventional thresholds, which explains insurer reluctance to approve without strict prior-authorization criteria [7].

Compounded tesamorelin is almost universally excluded from commercial insurance coverage and is purchased cash-pay. Prices from licensed 503A pharmacies in Florida typically range from $150 to $400 per month depending on concentration, vial count, and pharmacy margins.

Comparison: Branded Egrifta vs. Compounded Tesamorelin in Florida

| Feature | Branded Egrifta SV | Compounded Tesamorelin (503A) | |---|---|---| | FDA approval | Yes (HALS indication) | No | | cGMP manufacturing | Yes | Pharmacy-standard (USP <797>) | | Florida legal | Yes, with valid Rx | Yes, with valid Rx from licensed 503A pharmacy | | Insurance coverage | Possible (prior auth required) | Typically none | | Monthly cost (approx.) | $5,000+ list / varies with insurance | $150, $400 cash-pay | | Off-label use | Legal, physician discretion | Legal with documented clinical need | | Telehealth prescribing | Yes (FL Statute 456.47) | Yes (FL Statute 456.47) |

What Clinicians and Patients Should Know Right Now

The legal picture for tesamorelin in Florida is more settled than for many other peptides. FDA approval of the branded product removes the ambiguity that surrounds, for example, BPC-157 or CJC-1295, which have no approved versions and face active FDA scrutiny. Tesamorelin's non-scheduled status means no DEA registration is required for prescribers beyond their standard DEA registration for their practice.

The areas requiring real clinical and legal attention are: (1) ensuring the prescribing indication is documented, (2) using only pharmacies with verifiable Florida licensure, and (3) counseling patients who inquire about "research chemical" sources about the associated legal and safety risks.

The Endocrine Society's position on GHRH therapy states that "tesamorelin is the only approved pharmacological therapy specifically for HIV-associated lipodystrophy and has demonstrated consistent VAT reduction across trials with an acceptable safety profile" [4]. That endorsement does not extend to off-label or unregulated use, a distinction every Florida prescriber should communicate clearly to patients.